Omentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progression

Obesity Reviews

Volumn 17, Issue 11, 2016, Pages 1015-1029

  Chkourko Gusky, H ^a   Diedrich, J ^a   MacDougald, O A ^b   Podgorski, I ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adipose tissue; bone metastasis; MAT; omental metastasis; WAT

Indexed keywords

ADIPOCYTOKINE; ANGIOGENIC FACTOR; CYTOKINE; LIPID; LIPIDOME;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ANGIOGENESIS; BONE MARROW; BONE METASTASIS; BONE REMODELING; CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL METABOLISM; HUMAN; IMMUNOCOMPETENT CELL; INTRACELLULAR SIGNALING; INTRACELLULAR TRANSPORT; METASTASIS; OBESITY; OMENTUM; OVARY CANCER; REVIEW; TUMOR MICROENVIRONMENT; WHITE ADIPOSE TISSUE;

EID: 84990822383     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12450     Document Type: Review

References (165)

1. Bays HE, Gonzalez-Campoy JM, Bray GA et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008; 6: 343–368.
2. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697–738.
3. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009; 54: 1847–1856.
4. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001; 60: 329–339.
5. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006; 55: 1537–1545.
6. Wang P, Mariman E, Renes J, Keijer J. The secretory function of adipocytes in the physiology of white adipose tissue. J Cell Physiol 2008; 216: 3–13.
7. Conde J, Scotece M, Gomez R et al. Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. Biofactors 2011; 37: 413–420.
8. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6: 772–783.
9. NCI. Metastatic Canc 2013. URL http://www.cancer.gov/types/metastatic-cancer
10. Gerber SA, Rybalko VY, Bigelow CE et al. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 2006; 169: 1739–1752.
11. Nieman KM, Kenny HA, Penicka CV et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011; 17: 1498–1503.
12. He Y, Wu AC, Harrington BS et al. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene 2016; 35: 468–478.
13. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010; 177: 1053–1064.
14. Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 2006; 7: 925–934.
15. Wilkosz S, Ireland G, Khwaja N et al. A comparative study of the structure of human and murine greater omentum. Anat Embryol (Berl) 2005; 209: 251–261.
16. Ellis H. The aetiology of post-operative abdominal adhesions. An experimental study. Br J Surg 1962; 50: 10–16.
17. Hall JC, Heel KA, Papadimitriou JM, Platell C. The pathobiology of peritonitis. Gastroenterology 1998; 114: 185–196.
18. Chamorro M, Carceller F, Llanos C, Rodriguez-Alvarino A, Colmenero C, Burgueno M. The effect of omental wrapping on nerve graft regeneration. Br J Plast Surg 1993; 46: 426–429.
19. Goldsmith HS. Role of the omentum in the treatment of Alzheimer's disease. Neurol Res 2001; 23: 555–564.
20. Chau YY, Bandiera R, Serrels A et al. Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source. Nat Cell Biol 2014; 16: 367–375.
21. Sanchez-Gurmaches J, Hung CM, Sparks CA, Tang Y, Li H, Guertin DA. PTEN loss in the Myf5 lineage redistributes body fat and reveals subsets of white adipocytes that arise from Myf5 precursors. Cell Metab 2012; 16: 348–362.
22. Berry R, Rodeheffer MS, Rosen CJ, Horowitz MC. Adipose tissue residing progenitors adipocyte lineage progenitors and adipose derived stem cells (ADSC). Curr Mol Biol Rep 2015; 1: 101–109.
23. Berry R, Rodeheffer MS. Characterization of the adipocyte cellular lineage in vivo. Nat Cell Biol 2013; 15: 302–308.
24. Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39–48.
25. Liu J, Fox CS, Hickson DA et al. Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study. J Clin Endocrinol Metab 2010; 95: 5419–5426.
26. Doig T, Monaghan H. Sampling the omentum in ovarian neoplasia: when one block is enough. Int J Gynecol Cancer 2006; 16: 36–40.
27. Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 2013; 1831: 1533–1541.
28. Brasaemle DL, Subramanian V, Garcia A, Marcinkiewicz A, Rothenberg A. Perilipin A and the control of triacylglycerol metabolism. Mol Cell Biochem 2009; 326: 15–21.
29. Clark R, Krishnan V, Schoof M et al. Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models. Am J Pathol 2013; 183: 576–591.
30. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012; 491: 364–373.
31. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metab 2013; 18: 153–161.
32. Baenke F, Peck B, Miess H, Schulze A. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech 2013; 6: 1353–1363.
33. Ros S, Santos CR, Moco S et al. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Canc Discov 2012; 2: 328–343.
34. Daniels VW, Smans K, Royaux I, Chypre M, Swinnen JV, Zaidi N. Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment. PLoS One 2014; 9: e106913.
35. Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Power surge: supporting cells “fuel” cancer cell mitochondria. Cell Metab 2012; 15: 4–5.
36. Schwartz B, Yehuda-Shnaidman E. Putative role of adipose tissue in growth and metabolism of colon cancer cells. Front Oncol 2014; 4: 164.
37. Watson DG, Tonelli F, Alossaimi M et al. The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cell Signal 2013; 25: 1011–1017.
38. Tonelli F, Alossaimi M, Natarajan V et al. The roles of sphingosine kinase 1 and 2 in regulating the metabolome and survival of prostate cancer cells. Biomolecules 2013; 3: 316–333.
39. Manzi L, Costantini L, Molinari R, Merendino N. Effect of dietary omega-3 polyunsaturated fatty acid DHA on glycolytic enzymes and Warburg phenotypes in cancer. Biomed Res Int 2015; 2015: 137097.
40. Vaughan M. The production and release of glycerol by adipose tissue incubated in vitro. J Biol Chem 1962; 237: 3354–3358.
41. Maeda N, Funahashi T, Shimomura I. Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9. Nat Clin Pract Endocrinol Metab 2008; 4: 627–634.
42. Langin D. Control of fatty acid and glycerol release in adipose tissue lipolysis. C R Biol 2006; 329: 598–607; discussion 653-5.
43. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008; 7: 489–503.
44. Furuhashi M, Tuncman G, Gorgun CZ et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007; 447: 959–965.
45. Hertzel AV, Bernlohr DA. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab 2000; 11: 175–180.
46. Hardaway AL, Podgorski I. IL-1beta, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies. Future Med Chem 2013; 5: 1089–1108.
47. Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 2005; 280: 12888–12895.
48. Elmasri H, Karaaslan C, Teper Y et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. FASEB J 2009; 23: 3865–3873.
49. Cataltepe O, Arikan MC, Ghelfi E et al. Fatty acid binding protein 4 is expressed in distinct endothelial and non-endothelial cell populations in glioblastoma. Neuropathol Appl Neurobiol 2012; 38: 400–410.
50. Balaban S, Lee LS, Schreuder M, Hoy AJ. Obesity and cancer progression: is there a role of fatty acid metabolism? Biomed Res Int 2015; 2015: 274585.
51. Doege H, Stahl A. Protein-mediated fatty acid uptake: novel insights from in vivo models. Physiology (Bethesda) 2006; 21: 259–268.
52. Schneider H, Staudacher S, Poppelreuther M, Stremmel W, Ehehalt R, Fullekrug J. Protein mediated fatty acid uptake: synergy between CD36/FAT-facilitated transport and acyl-CoA synthetase-driven metabolism. Arch Biochem Biophys 2014; 546: 8–18.
53. Yam D, Ben-Hur H, Dgani R, Fink A, Shani A, Berry EM. Subcutaneous, omentum and tumor fatty acid composition, and serum insulin status in patients with benign or cancerous ovarian or endometrial tumors. Do tumors preferentially utilize polyunsaturated fatty acids? Cancer Lett 1997; 111: 179–185.
54. Shimotsuma M, Takahashi T, Kawata M, Dux K. Cellular subsets of the milky spots in the human greater omentum. Cell Tissue Res 1991; 264: 599–601.
55. Krist LF, Eestermans IL, Steenbergen JJ et al. Cellular composition of milky spots in the human greater omentum: an immunochemical and ultrastructural study. Anat Rec 1995; 241: 163–174.
56. Mandache E, Moldoveanu E, Savi G. The involvement of omentum and its milky spots in the dynamics of peritoneal macrophages. Morphol Embryol (Bucur) 1985; 31: 137–142.
57. Rangel-Moreno J, Moyron-Quiroz JE, Carragher DM et al. Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens. Immunity 2009; 30: 731–743.
58. Dux K, Rouse RV, Kyewski B. Composition of the lymphoid cell populations from omental milky spots during the immune response in C57BL/Ka mice. Eur J Immunol 1986; 16: 1029–1032.
59. Funda D, Holub M, Sykora V. Development of the cellular response in the mouse omentum after intraperitoneal immunization. APMIS 1993; 101: 939–945.
60. Van Vugt E, Van Rijthoven EA, Kamperdijk EW, Beelen RH. Omental milky spots in the local immune response in the peritoneal cavity of rats. Anat Rec 1996; 244: 235–245.
61. Tsujimoto H, Takhashi T, Hagiwara A et al. Site-specific implantation in the milky spots of malignant cells in peritoneal dissemination: immunohistochemical observation in mice inoculated intraperitoneally with bromodeoxyuridine-labelled cells. Br J Cancer 1995; 71: 468–472.
62. Hagiwara A, Takahashi T, Sawai K et al. Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res 1993; 53: 687–692.
63. Khan SM, Funk HM, Thiolloy S et al. In vitro metastatic colonization of human ovarian cancer cells to the omentum. Clin Exp Metastasis 2010; 27: 185–196.
64. Krist LF, Kerremans M, Broekhuis-Fluitsma DM, Eestermans IL, Meyer S, Beelen RH. Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavity. Cancer Immunol Immunother 1998; 47: 205–212.
65. Sorensen EW, Gerber SA, Sedlacek AL, Rybalko VY, Chan WM, Lord EM. Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol Res 2009; 45: 185–194.
66. Lopes Cardozo AM, Gupta A, Koppe MJ et al. Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol 2001; 27: 359–363.
67. Robinson-Smith TM, Isaacsohn I, Mercer CA et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res 2007; 67: 5708–5716.
68. Takemori N, Hirai K, Onodera R, Saito N, Namiki M. Light and electron microscope study of splenoportal milky spots in New Zealand black mice: comparison between splenoportal milky spots and aberrant spleens. J Anat 1995; 186: 287–299.
69. Schumann T, Adhikary T, Wortmann A et al. Deregulation of PPARbeta/delta target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment. Oncotarget 2015; 6: 13416–13433.
70. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–1186.
71. Zhang QX, Magovern CJ, Mack CA, Budenbender KT, Ko W, Rosengart TK. Vascular endothelial growth factor is the major angiogenic factor in omentum: mechanism of the omentum-mediated angiogenesis. J Surg Res 1997; 67: 147–154.
72. Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev 2015; 34: 19–40.
73. Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2011; 2: 1117–1133.
74. Georgiou KR, Hui SK, Xian CJ. Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy. Am J Stem Cells 2012; 1: 205–224.
75. Cawthorn WP, Scheller EL, Learman BS et al. Bone marrow adipose tissue is an endocrine organ that contributes to increased circulating adiponectin during caloric restriction. Cell Metab 2014; 20: 368–375.
76. Bassett WW, Cooperberg MR, Sadetsky N et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology 2005; 66: 1060–1065.
77. Keto CJ, Aronson WJ, Terris MK et al. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU Int 2012; 110: 492–498.
78. Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007; 109: 1192–1202.
79. von Drygalski A, Tran TB, Messer K et al. Obesity is an independent predictor of poor survival in metastatic breast cancer: retrospective analysis of a patient cohort whose treatment included high-dose chemotherapy and autologous stem cell support. Int J Breast Canc 2011; 2011: 523276.
80. Ryden M, Uzunel M, Hard JL et al. Transplanted bone marrow-derived cells contribute to human adipogenesis. Cell Metab 2015; 22: 408–417.
81. Tavassoli M. Ultrastructural development of bone marrow adipose cell. Acta Anat (Basel) 1976; 94: 65–77.
82. Chen J, Shi Y, Regan J, Karuppaiah K, Ornitz DM, Long F. Osx-Cre targets multiple cell types besides osteoblast lineage in postnatal mice. PLoS One 2014; 9: e85161.
83. Liu Y, Strecker S, Wang L et al. Osterix-cre labeled progenitor cells contribute to the formation and maintenance of the bone marrow stroma. PLoS One 2013; 8: e71318.
84. Bianco P, Cao X, Frenette PS et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med 2013; 19: 35–42.
85. Mizoguchi T, Pinho S, Ahmed J et al. Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. Dev Cell 2014; 29: 340–349.
86. Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 2014; 15: 154–168.
87. Worthley DL, Churchill M, Compton JT et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell 2015; 160: 269–284.
88. Berendsen AD, Olsen BR. Osteoblast-adipocyte lineage plasticity in tissue development, maintenance and pathology. Cell Mol Life Sci 2014; 71: 493–497.
89. Wiren KM, Chapman Evans A, Zhang XW. Osteoblast differentiation influences androgen and estrogen receptor-alpha and -beta expression. J Endocrinol 2002; 175: 683–694.
90. Reim NS, Breig B, Stahr K et al. Cortical bone loss in androgen-deficient aged male rats is mainly caused by increased endocortical bone remodeling. J Bone Miner Res 2008; 23: 694–704.
91. Ottewell PD, Wang N, Meek J et al. Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr Relat Cancer 2014; 21: 769–781.
92. Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci 2009; 66: 236–253.
93. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005; 146: 1226–1235.
94. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008; 19: 129–137.
95. Ackert-Bicknell CL, Shockley KR, Horton LG, Lecka-Czernik B, Churchill GA, Rosen CJ. Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I. Endocrinology 2009; 150: 1330–1340.
96. Lecka-Czernik B, Moerman EJ, Grant DF, Lehmann JM, Manolagas SC, Jilka RL. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002; 143: 2376–2384.
97. Bennett CN, Ouyang H, Ma YL et al. Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res 2007; 22: 1924–1932.
98. Cawthorn WP, Bree AJ, Yao Y et al. Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a beta-catenin-dependent mechanism. Bone 2012; 50: 477–489.
99. Kang S, Bennett CN, Gerin I, Rapp LA, Hankenson KD, Macdougald OA. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem 2007; 282: 14515–14524.
100. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116: 1202–1209.
101. Scheller EL, Doucette CR, Learman BS et al. Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues. Nat Commun 2015; 6: 7808.
102. Doucette CR, Horowitz MC, Berry R et al. A high fat diet increases bone marrow adipose tissue (MAT) but does not alter trabecular or cortical bone mass in C57BL/6 J mice. J Cell Physiol 2015; 230: 2032–2037.
103. Botolin S, McCabe LR. Inhibition of PPARgamma prevents type I diabetic bone marrow adiposity but not bone loss. J Cell Physiol 2006; 209: 967–976.
104. Iwaniec UT, Turner RT. Failure to generate bone marrow adipocytes does not protect mice from ovariectomy-induced osteopenia. Bone 2013; 53: 145–153.
105. Tavassoli M. Marrow adipose cells. Histochemical identification of labile and stable components. Arch Pathol Lab Med 1976; 100: 16–18.
106. van der Pluijm G. Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 2011; 48: 37–43.
107. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1989; 8: 98–101.
108. Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7: 1194–1201.
109. Kaplan RN, Riba RD, Zacharoulis S et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820–827.
110. van der Horst G, van den Hoogen C, Buijs JT et al. Targeting of alpha(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. Neoplasia 2011; 13: 516–525.
111. Herroon MK, Rajagurubandara E, Hardaway AL et al. Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. Oncotarget 2013; 4: 2108–2123.
112. Unruh A, Ressel A, Mohamed HG et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003; 22: 3213–3220.
113. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50–56.
114. Jung Y, Kim JK, Shiozawa Y et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun 2013; 4: 1795.
115. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832–1837.
116. Kim D, Kim J, Yoon JH et al. CXCL12 secreted from adipose tissue recruits macrophages and induces insulin resistance in mice. Diabetologia 2014; 57: 1456–1465.
117. Pantel K, Muller V, Auer M, Nusser N, Harbeck N, Braun S. Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res 2003; 9: 6326–6334.
118. Aft R, Naughton M, Trinkaus K et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010; 11: 421–428.
119. Ottewell PD, Wang N, Brown HK et al. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res 2014; 20: 2922–2932.
120. Dunn LK, Mohammad KS, Fournier PG et al. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One 2009; 4: e6896.
121. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res 2005; 15: 57–62.
122. Ghajar CM, Peinado H, Mori H et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 2013; 15: 807–817.
123. Varma V, Yao-Borengasser A, Bodles AM et al. Thrombospondin-1 is an adipokine associated with obesity, adipose inflammation, and insulin resistance. Diabetes 2008; 57: 432–439.
124. Ramis JM, Franssen-van Hal NL, Kramer E et al. Carboxypeptidase E and thrombospondin-1 are differently expressed in subcutaneous and visceral fat of obese subjects. Cell Mol Life Sci 2002; 59: 1960–1971.
125. Catena R, Bhattacharya N, El Rayes T et al. Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Canc Discov 2013; 3: 578–589.
126. Li Y, Tong X, Rumala C, Clemons K, Wang S. Thrombospondin1 deficiency reduces obesity-associated inflammation and improves insulin sensitivity in a diet-induced obese mouse model. PLoS One 2011; 6: e26656.
127. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108: 785–791.
128. Li Y, Qi X, Tong X, Wang S. Thrombospondin 1 activates the macrophage Toll-like receptor 4 pathway. Cell Mol Immunol 2013; 10: 506–512.
129. Elbaz A, Wu X, Rivas D, Gimble JM, Duque G. Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med 2010; 14: 982–991.
130. Gunaratnam K, Vidal C, Gimble JM, Duque G. Mechanisms of palmitate-induced lipotoxicity in human osteoblasts. Endocrinology 2014; 155: 108–116.
131. Li GW, Xu Z, Chang SX et al. Influence of early zoledronic acid administration on bone marrow fat in ovariectomized rats. Endocrinology 2014; 155: 4731–4738.
132. Martin RB, Zissimos SL. Relationships between marrow fat and bone turnover in ovariectomized and intact rats. Bone 1991; 12: 123–131.
133. Guise TA, Mohammad KS, Clines G et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006; 12: 6213s–6216s.
134. Schneider A, Kalikin LM, Mattos AC et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005; 146: 1727–1736.
135. Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I. Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer. Clin Exp Metastasis 2015; 32: 353–368.
136. De Filippo K, Dudeck A, Hasenberg M et al. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood 2013; 121: 4930–4937.
137. Acharyya S, Oskarsson T, Vanharanta S et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012; 150: 165–178.
138. Shojaei F, Wu X, Malik AK et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b + Gr1+ myeloid cells. Nat Biotechnol 2007; 25: 911–920.
139. Yang L, DeBusk LM, Fukuda K et al. Expansion of myeloid immune suppressor Gr + CD11b + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6: 409–421.
140. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162–174.
141. El-Amm J, Freeman A, Patel N, Aragon-Ching JB. Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Canc 2013; 2013: 210686.
142. Basso FG, Silveira Turrioni AP, Hebling J, de Souza Costa CA. Zoledronic acid inhibits human osteoblast activities. Gerontology 2013; 59: 534–541.
143. Li GW, Chang SX, Fan JZ, Tian YN, Xu Z, He YM. Marrow adiposity recovery after early zoledronic acid treatment of glucocorticoid-induced bone loss in rabbits assessed by magnetic resonance spectroscopy. Bone 2013; 52: 668–675.
144. Pozzi S, Vallet S, Mukherjee S et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res 2009; 15: 5829–5839.
145. Morgans AK, Smith MR. Bone-targeted agents: preventing skeletal complications in prostate cancer. Urol Clin North Am 2012; 39: 533–546.
146. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–1468.
147. Smith MR, Halabi S, Ryan CJ et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 2014; 32: 1143–1150.
148. Coleman R, Powles T, Paterson A et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386: 1353–1361.
149. Sumida T. Clinical and experimental study on fatty acid composition of bone marrow lipid in hematologic disorders. Acta Med Nagasaki 1965; 9: 222–241.
150. Denizot Y, Dulery C, Trimoreau F, Desplat V, Praloran V. Arachidonic acid and human bone marrow stromal cells. Biochim Biophys Acta 1998; 1402: 209–215.
151. Denizot Y, Desplat V, Dulery C, Trimoreau F, Praloran V. Arachidonic acid and freshly isolated human bone marrow mononuclear cells. Mediators Inflamm 1999; 8: 31–35.
152. Brown MD, Hart CA, Gazi E, Bagley S, Clarke NW. Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs. Br J Cancer 2006; 94: 842–853.
153. Brown MD, Hart C, Gazi E, Gardner P, Lockyer N, Clarke N. Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer. Br J Cancer 2010; 102: 403–413.
154. Gazi E, Gardner P, Lockyer NP, Hart CA, Brown MD, Clarke NW. Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. J Lipid Res 2007; 48: 1846–1856.
155. Rose DP. Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies. Am J Clin Nutr 1997; 66(6 Suppl): 1513S–1522S.
156. Hughes-Fulford M, Li CF, Boonyaratanakornkit J, Sayyah S. Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer. Cancer Res 2006; 66: 1427–1433.
157. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997; 75: 1111–1118.
158. Kurtova AV, Xiao J, Mo Q et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 2015; 517: 209–213.
159. Ghosh J. Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophys Res Commun 2004; 315: 624–635.
160. Gao X, Grignon DJ, Chbihi T et al. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 1995; 46: 227–237.
161. Nie D, Hillman GG, Geddes T et al. Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res 1998; 58: 4047–4051.
162. Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, Jackson RT. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer 1999; 81: 1238–1242.
163. Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 1999; 83: 217–244.
164. Watkins BA, Li Y, Allen KG, Hoffmann WE, Seifert MF. Dietary ratio of (n-6)/(n-3) polyunsaturated fatty acids alters the fatty acid composition of bone compartments and biomarkers of bone formation in rats. J Nutr 2000; 130: 2274–2284.
165. Mamalakis G, Kafatos A, Kalogeropoulos N, Andrikopoulos N, Daskalopulos G, Kranidis A. Prostate cancer vs hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. Prostaglandins Leukot Essent Fatty Acids 2002; 66: 467–477.